TMEM106B

Across TCGA pan-cancer cohorts, TMEM106B RNA is linked to patient survival in 24 of 34 cancer types, making it the most broadly survival-associated TMEM106B data layer compared with 7 for mutation status and 6 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher TMEM106B RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated TMEM106B expression acts as an unfavorable survival marker, although some lineages such as KIRC and COAD show a favorable association.

KIRC, CESC, and COAD are the cancer types where TMEM106B RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	DFS	Median	All	0.732	0.504	<.001	78	view →
CESC	DFS	Median	All	0.430	0.662	.002	36	view →
COAD	OS	Tertile	IV	0.660	0.353	.013	26	view →
UVM	DFS	Quartile	III,IV	0.183	0.814	.001	26	view →
PRAD	DFS	Quartile	All	0.915	0.741	<.001	24	view →
KIRP	OS	Median	IV	0.041	0.524	.013	20	view →
LIHC	DFS	Tertile	All	0.371	0.518	.011	16	view →
ACC	DFS	Tertile	III,IV	0.551	0.087	.004	15	view →
PAAD	OS	Median	All	0.347	0.602	.007	13	view →
STAD	DFS	Quartile	IV	0.164	0.655	.008	12	view →
MESO	DFS	Median	III,IV	0.232	0.608	.034	12	view →
CHOL	OS	Median	All	0.832	0.403	.016	11	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 24 lineages.

TMEM106B–KIRC (DFS)

Open the KIRC breakdown →